MDxHealth Reports Mixed Q4 2025 Results, Misses Revenue Estimates; Shares Dip
MDxHealth SA (NASDAQ:MDXH), a commercial-stage company focused on urology precision diagnostics, announced its financial results for the fourth quarter and full year ended December 31, 2025. The report revealed continued top-line growth but a revenue miss against analyst expectations, sending shares lower in after-hours trading.
Earnings and Revenue Versus Estimates
The company's fourth-quarter performance presented a mixed picture when measured against Wall Street forecasts. While the company demonstrated solid year-over-year growth, it fell short of consensus estimates on the top line.
- Q4 2025 Revenue: $29.5 million, representing a 19% increase from the $24.7 million reported in Q4 2024.
- Q4 2025 Analyst Revenue Estimate: $31.1 million.
- Q4 2025 EPS (Non-GAAP): A loss of $0.17 per share.
- Q4 2025 Analyst EPS Estimate: A loss of $0.13 per share.
For the full year 2025, the company reported revenue of $107.9 million, a 20% increase over 2024's $90.0 million. The annual net loss improved to $33.5 million from $38.1 million in the prior year.
Market Reaction and Price Action
The market's immediate reaction to the earnings release was negative. Following the announcement, MDxHealth shares traded lower in the after-market session. This price action appears to be a direct response to the company's revenue miss for the quarter, as investors weigh the deceleration from the 20% full-year growth rate against the high expectations embedded in analyst estimates.
Key Highlights from the Press Release
Beyond the headline numbers, management highlighted several operational milestones and a strategic shift in its test portfolio:
- Accelerating Liquid-Based Portfolio: A significant highlight was the explosive 128% year-over-year growth in liquid-based test volumes (including ExoDx, Select mdx, Resolve mdx) to 27,486 tests in Q4. This contrasts with a 5% decline in tissue-based test volumes (Confirm mdx and GPS), signaling a successful integration and commercial push for its newer, non-invasive offerings.
- Path to Profitability: The company emphasized improved operational leverage. Full-year Adjusted EBITDA was a loss of $1.1 million, a substantial 92% improvement from a $14.7 million loss in 2024. Gross margin expanded to 64.5% for the year, up 3.3 percentage points, driven by economies of scale.
- 2026 Outlook: MDxHealth maintained its previously issued 2026 revenue guidance of $137 to $140 million, which would represent year-over-year growth of 27% to 30%. This outlook is notably higher than the current analyst sales estimate of $136.6 million for the full year 2026. The company also reiterated its target of achieving a 10% Adjusted EBITDA margin run rate by the end of 2026.
Forward Guidance Versus Analyst Expectations
The company's 2026 revenue guidance range presents an optimistic view compared to current market expectations. By projecting $137-$140 million, management is forecasting growth at the high end of, or slightly above, the analyst consensus. This forward-looking confidence, centered on the accelerating liquid-based portfolio, may serve to counterbalance some of the near-term disappointment from the Q4 revenue miss.
Conclusion
MDxHealth's fourth-quarter results underscore a company in transition. While it missed quarterly revenue targets, the underlying story is one of strategic portfolio shift and improving financial discipline. The dramatic growth in its liquid biopsy tests and a clear path toward EBITDA profitability are positive long-term indicators. However, the market's negative reaction highlights the heightened scrutiny on quarterly execution as the company invests to capture its stated growth ambitions. The maintained robust guidance for 2026 will be a key focal point for investors assessing whether the current quarter's miss is a temporary setback or a trend.
For a detailed breakdown of future earnings estimates and historical performance, review the MDxHealth earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an endorsement, or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.